The aryl hydrocarbon receptor: A review of its role in the physiology and pathology of the integument and its relationship to the tryptophan metabolism

International Journal of Tryptophan Research

Volumn 8, Issue 1, 2015, Pages 7-18

  Noakes, Rowland ^a  

^a Queensland Institute of Dermatology and Veracity Clinical Research   (Australia)

Author keywords

Aryl hydrocarbon receptor; Cellular oxidation antioxidation; Epidermal barrier; Immune regulation; Melanogenesis; Tryptophan metabolism; Uv exposure

Indexed keywords

EID: 84929929841     PISSN: None     EISSN: 11786469     Source Type: Journal    
DOI: 10.4137/IJTR.S19985     Document Type: Article

References (123)

1. Denison MS, Nagy SR. Activation of the aryl hydrocarbon receptor by structur-ally diverse exogenous and endogenous chemicals. Annu Rev Pharmacol Toxicol. 2003;43(1):309-34.
2. Carlstedt-Duke JM. Tissue distribution of the receptor for 2,3,7,8-tetrachloro-dibenzo-p-dioxin in the rat. Cancer Res. 1979;39(8):3172-6.
3. Johansson G, Gillner M, Högberg B, Gustafsson JA. The TCDD receptor in rat intestinal mucosa and its possible dietary ligands. Nutr Cancer. 1981;3(3):134-44.
4. Agostinis P, Garmyn M, Van Laethem A. The Aryl hydrocarbon receptor: an illuminating effector of the UVB response. Sci Signal. 2007;2007(403):e49.
5. Enan E, Matsumura F. Identification of c-Src as the integral component of the cytosolic Ah receptor complex, transducing the signal of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) through the protein phosphorylation pathway. Biochem Pharmacol. 1996;52(10):1599-612.
6. Fritsche E, Schafer C, Calles C, et al. Lightening up the UV response by identi-fication of the arylhydrocarbon receptor as a cytoplasmatic target for ultraviolet B radiation. Proc Natl Acad Sci U S A. 2007;104(21):8851-6.
7. Furue M, Takahara M, Nakahara T, Uchi H. Role of AhR/ARNT system in skin homeostasis. Arch Dermatol Res. 2014;306(9):769-79.
8. Schnekenburger M, Peng L, Puga A. HDAC1 bound to the Cyp1a1 promoter blocks histone acetylation associated with Ah receptor-mediated trans-activation. Biochim Biophys Acta. 2007;1769:569-78.
9. Pollenz RS. The mechanism of AH receptor protein down-regulation (degrada-tion) and its impact on AH receptor-mediated gene regulation. Chem Biol Inter-act. 2002;141:41-61.
10. Mimura J, Ema M, Sogawa K, Fujii-Kuriyama Y. Identification of a novel mechanism of regulation of Ah (dioxin) receptor function. Genes Dev. 1999;13(1):20-5.
11. Matthews J, Gustafsson JA. Estrogen receptor and aryl hydrocarbon receptor signaling pathways. Nucl Recept Signal. 2006;4:e016.
12. Puga A, Ma C, Marlowe JL. The aryl hydrocarbon receptor cross-talks with mul-tiple signal transduction pathways. Biochem Pharmacol. 2009;77:713-22.
13. Murphy KA, Quadro L, White LA. The intersection between the Aryl hydrocarbon receptor (AhR)- and retinoic acid-signaling pathways. Vitam Horm. 2007;75:33-67.
14. Tian Y. Ah receptor and NF-κB interplay on the stage of epigenome. Biochem Pharmacol. 2009;77:670-80.
15. Vogel CF, Khan EM, Leung PS, et al. Cross-talk between Aryl hydrocarbon receptor and the inflammatory response a role for nuclear factor-κB. J Biol Chem. 2014;289(3):1866-75.
16. Rannug U, Rannug A, Sjöberg U, Li H, Westerholm R, Bergman J. Structure elucidation of two tryptophan-derived, high affinity Ah receptor ligands. Chem Biol. 1995;2(12):841-5.
17. Wang C, Ye Z, Kijlstra A, Zhou Y, Yang P. Activation of the aryl hydrocarbon receptor affects activation and function of human monocyte-derived dendritic cells. Clin Exp Immunol. 2014;177(2):521-30.
18. Mándi Y, Vécsei L. The kynurenine system and immunoregulation. J Neural Transm. 2012;119(2):197-209.
19. Mezrich JD, Fechner JH, Zhang X, Johnson BP, Burlingham WJ, Bradfield CA. An interaction between kynurenine and the aryl hydrocarbon receptor can gen-erate regulatory T cells. J Immunol. 2010;185(6):3190-8.
20. DiNatale BC, Murray IA, Schroeder JC, et al. Kynurenic acid is a potent endo-genous aryl hydrocarbon receptor ligand that synergistically induces inter-leukin-6in the presence of inflammatory signaling. Toxicol Sci. 2010;115(1):89-97.
21. Lowe MM, Mold JE, Kanwar B, et al. Identification of cinnabarinic acid as a novel endogenous Aryl hydrocarbon receptor ligand that drives IL-22 produc-tion. PLoS One. 2014;9(2):e87877.
22. Widner B, Werner ER, Schennach H, Wachter H, Fuchs D. Simultane-ous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem. 1997;43(12):2424-6.
23. Heath-Pagliuso S, Rogers WJ, Tullis K, et al. Activation of the Ah receptor by tryptophan and tryptophan metabolites. Biochemistry. 1998;37:11508-15.
24. Bankoti J, Rase B, Simones T, Shepherd DM. Functional and phenotypic effects of AhR activation in inflammatory dendritic cells. Toxicol Appl Pharmacol. 2010;246:18-28.
25. Quintana FJ. LeA(H)Rning self-control. Cell Res. 2014;24(10):1155-6.
26. Noakes R, Spelman L, Williamson R. Is the L-tryptophan metabolite quinolinic acid responsible for eosinophilic fasciitis? Clin Exp Med. 2006;6(2):60-4.
27. Van Voorhis M, Fechner JH, Zhang X, Mezrich JD. The Aryl hydrocarbon receptor: a novel target for immunomodulation in organ transplantation. Trans-plantation. 2013;95(8):983.
28. Quintana FJ, Basso AS, Iglesias AH, et al. Control of Treg and TH17 cell differentiation by the aryl hydrocarbon receptor. Nature. 2008;453(7191):65-71.
29. Duarte JH, Di Meglio P, Hirota K, Ahlfors H, Stockinger B. Differential influ-ences of the Aryl hydrocarbon receptor on Th17mediated responses in vitro and in vivo. PLoS One. 2013;8(11):e79819.
30. Jux B, Kadow S, Esser C. Langerhans cell maturation and contact hyper-sensitivity are impaired in aryl hydrocarbon receptornull mice. J Immunol. 2009;182(11):6709-17.
31. Nguyen NT, Kimura A, Nakahama T, et al. Aryl hydrocarbon receptor nega-tively regulates dendritic cell immunogenicity via a kynurenine-dependent mechanism. Proc Natl Acad Sci U S A. 2010;107(46):19961-6.
32. Noakes RR. Effects of tranilast on the urinary excretion of kynurenic and quinolinic acid under conditions of L tryptophan loading. Int. J. Tryptophan Res. 2013;6:67-71.
33. Hu W, Zhao J, Pei G. Activation of aryl hydrocarbon receptor (ahr) by tranil-ast, an anti-allergy drug, promotes miR-302 expression and cell reprogramming. J Biol Chem. 2013;288(32):22972-84.
34. O'Donnell EF, Saili KS, Koch DC, et al. The anti-inflammatory drug leflunomide is an agonist of the aryl hydrocarbon receptor. PLoS One. 2010;5(10):e13128.
35. Chen Y, Guillemin GJ. Kynurenine pathway metabolites in humans: disease and healthy states. Int J Tryptophan Res. 2009;2:1-19.
36. Bittinger MA, Nguyen LP, Bradfield CA. Aspartate aminotransferase gener-ates proagonists of the aryl hydrocarbon receptor. Mol Pharmacol. 2003;64:550-556.
37. Creed D. The photophysics and photochemistry of the near-UV absorbing amino acids-I. Tryptophan and its simple derivatives. Photochem Photobiol. 1984;39(4):537-62.
38. Diani-Moore S, Labitzke E, Brown R, Garvin A, Wong L, Rifkind AB. Sun-light generates multiple tryptophan photoproducts eliciting high efficacy CYP1 A induction in chick hepatocytes and in vivo. Toxicol Sci. 2006;90(1):96-110.
39. Esser C, Bargen I, Weighardt H, Haarmann-Stemmann T, Krutmann J. Functions of the aryl hydrocarbon receptor in the skin. Semin Immunopathol. 2013;35(6):677-91.
40. Mimura J, Yamashita K, Nakamura K, et al. Loss of teratogenic response to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in mice lacking the Ah (dioxin) receptor. Genes Cells. 1997;2(10):645-54.
41. Schmidt JV, Su GH, Reddy JK, Simon MC, Bradfield CA. Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development. Proc Natl Acad Sci U S A. 1996;93(13):6731-6.
42. Gonzalez FJ, Fernandez-Salguero P. The aryl hydrocarbon receptor studies using the AHR-null mice. Drug Metab Dispos. 1998;26(12):1194-8.
43. Barouki R, Coumoul X, Fernandez-Salguero PM. The aryl hydrocarbon receptor, more than a xenobiotic-interacting protein. FEBS Lett. 2007;581:3608-15.
44. Denison MS, Whitlock JP. Xenobiotic-inducible transcription of cytochrome P450genes. J Biol Chem. 1995;270(31):18175-8.
45. Tsuji G, Takahara M, Uchi H, et al. Identification of ketoconazole as an AhR-Nrf2 activator in cultured human keratinocytes: the basis of its anti-inflamma-tory effect. J Invest Dermatol. 2011;132(1):59-68.
46. Miao W, Hu L, Scrivens PJ, Batist G. Transcriptional regulation of NF-E2 p45-related factor (NRF2) expression by the aryl hydrocarbon receptor-xenobiotic response element signaling pathway: direct cross-talk between phase I and II drug-metabolizing enzymes. J Biol Chem. 2005;280(21):20340-8.
47. Degner SC, Papoutsis AJ, Selmin O, Romagnolo DF. Targeting of aryl hydro-carbon receptor-mediated activation of cyclooxygenase-2 expression by the indole-3-carbinol metabolite 3, 3'-diindolylmethane in breast cancer cells. J Nutr. 2009;139(1):26-32.
48. Ono Y, Torii K, Fritsche E, et al. Role of the aryl hydrocarbon receptor in tobacco smoke extract-induced matrix met alloproteinase-1 expression. Exp Dermatol. 2013;22(5):349-53.
49. Escuin-Ordinas H, Atefi M, Fu Y, et al. COX-2inhibition prevents the appear-ance of cutaneous squamous cell carcinomas accelerated by BRAF inhibitors. Mol Oncol. 2014;8(2):250-60.
50. Quan T, Little E, Quan H, Qin Z, Voorhees JJ, Fisher GJ. Elevated matrix met alloproteinases and collagen fragmentation in photodamaged human skin: impact of altered extracellular matrix microenvironment on dermal fibroblast function. J Invest Dermatol. 2013;133(5):1362.
51. Kanagawa Y, Matsumoto S, Koike S, et al. Association of clinical findings in Yusho patients with serum concentrations of polychlorinated biphenyls, poly-chlorinated quarterphenyls and 2,3,4,7,8-pentachlorodibenzofuran more than 30 years after the poisoning event. Environ Health. 2008;7(1):47.
52. Dunagin WG. Cutaneous signs of systemic toxicity due to dioxins and related chemicals. J Am Acad Dermatol. 1984;10(4):688-700.
53. Luecke S, Backlund M, Jux B, Esser C, Krutmann J, Rannug A. The aryl hydro-carbon receptor (AHR), a novel regulator of human melanogenesis. Pigment Cell Melanoma Res. 2010;23(6):828-33.
54. Lennartsson J, Rönnstrand L. Stem cell factor receptor/c-Kit: from basic science to clinical implications. Physiol Rev. 2012;92(4):1619-49.
55. Jux B, Kadow S, Luecke S, Rannug A, Krutmann J, Esser C. The Aryl hydrocar-bon receptor mediates UVB radiation-induced skin tanning. J Invest Dermatol. 2010;131(1):203-10.
56. Kalinin A, Marekov LN, Steinert PM. Assembly of the epidermal cornified cell envelope. J Cell Sci. 2001;114(17):3069-70.
57. Weidinger S, Illig T, Baurecht H, et al. Loss-of-function variations within the filaggrin gene predispose for atopic dermatitis with allergic sensitizations. J Allergy ClinImmunol. 2006;118(1):214-9.
58. Tauchi M, Hida A, Negishi T, et al. Constitutive expression of aryl hydrocar-bon receptor in keratinocytes causes inflammatory skin lesions. Mol Cell Biol. 2005;25(21):9360-8.
59. Sääf A, Pivarcsi A, Winge MC, et al. Characterization of EGFR and ErbB2 expres-sion in atopic dermatitis patients. Arch Dermatol Res. 2012;304(10):773-80.
60. Zhang Z, Xiao C, Gibson AM, Bass SA, Khurana Hershey GK. EGFR sig-naling blunts allergen-induced IL-6 production and Th17 responses in the skin and attenuates development and relapse of atopic dermatitis. J Immunol. 2014;192(3):859-66.
61. Sutter CH, Yin H, Li Y, et al. EGF receptor signaling blocks aryl hydrocar-bonreceptor-mediated transcription and cell differentiation in human epidermal keratinocytes. Proc Natl Acad Sci U S A. 2009;106(11):4266-71.
62. Matsue H, Cruz PD Jr, Bergstresser PR, Takashima A. Cytokine expression by epidermal cell subpopulations. J Invest Dermatol. 1992;99:42S-5S.
63. Henley DV, Bellone CJ, Williams DA, Ruh MF. MAPK signaling pathways modulate IL-1beta expression in human keratinocytes. Arch Biochem Biophys. 2004;424(1):112-8.
64. Podechard N, Lecureur V, Le Ferrec E, et al. Interleukin-8induction by the environmental contaminant benzo (a) pyrene is aryl hydrocarbon receptor-dependent and leads to lung inflammation. Toxicol Lett. 2008;177(2):130-7.
65. Bennett CL, van Rijn E, Jung S, et al. Inducible ablation of mouse Langer-hans cells diminishes but fails to abrogate contact hypersensitivity. J Cell Biol. 2005;169(4):569-76.
66. Lowes MA, Kikuchi T, Fuentes-Duculan J, et al. Psoriasis vulgaris lesions contain discrete populations of Th1 and Th17 T cells. J Invest Dermatol. 2008;128(5):1207-11.
67. Bettelli E, Oukka M, Kuchroo VK. TH-17cells in the circle of immunity and autoimmunity. Nat Immunol. 2007;8(4):345-50.
68. Veldhoen M, Hirota K, Westendorf AM, et al. The aryl hydrocarbon recep-tor links TH17-cell-mediated autoimmunity to environmental toxins. Nature. 2008;453(7191):106-9.
69. Fujita H, Nograles KE, Kikuchi T, Gonzalez J, Carucci JA, Krueger JG. Human Langerhans cells induce distinct IL-22-producing CD4+ T cells lacking IL-17 production. Proc Natl Acad Sci U S A. 2009;106(51):21795-800.
70. Tan NS, Wahli W. The emerging role of Nrf2in dermatotoxicology. EMBO Mol Med. 2014;6(4):431-3.
71. Saurat JH, Kaya G, Saxer-Sekulic N, et al. The cutaneous lesions of dioxin exposure: lessons from the poisoning of Victor Yushchenko. Toxicol Sci. 2012;125(1):310-7.
72. Panteleyev AA, Bickers DR. Dioxin-induced chloracne-reconstructing the cel-lular and molecular mechanisms of a classic environmental disease. Exp Derma-tol. 2006;15(9):705-30.
73. Osborne R, Greenlee WF. 2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) enhances terminal differentiation of cultured human epidermal cells. Toxicol Appl Pharmacol. 1985;77(3):434-43.
74. Gaido KW, Maness SC, Leonard LS, Greenlee WF. 2,3,7,8-Tetrachlorod-ibenzo-p-dioxin-dependent regulation of transforming growth factors-alpha and-beta 2 expression in a human keratinocyte cell line involves both transcrip-tional and post-transcriptional control. J Biol Chem. 1992;267(34):24591-95.
75. Greenlee WF, Dold KM, Osborne R. Actions of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) on human epidermal keratinocytes in culture. In Vitro Cell Dev Biol. 1985;21(9):509-12.
76. Cunliffe WJ, Williams M, Edwards JC, et al. An explanation for chloracne - an industrial hazard. Acta Derm Venereol. 1974;55(3):211-4.
77. Schäfer M, Willrodt AH, Kurinna S, et al. Activation of Nrf2in keratino-cytes causes chloracne (MADISH)-like skin disease in mice. EMBO Mol Med. 2014;6(4):442-57.
78. Gawkrodger DJ. Occupational skin cancers. Occup Med. 2004;54(7):458-63.
79. Shimizu Y, Nakatsuru Y, Ichinose M, et al. Benzo[a]pyrene carcinogenicity is lost in mice lacking the aryl hydrocarbon receptor. Proc Natl Acad Sci U S A. 2000;97(2):779-82.
80. Di Meglio P, Duarte JH, Ahlfors H, et al. Activation of the Aryl hydrocar-bon receptor dampens the severity of inflammatory skin conditions. Immunity. 2014;40(6):989-1001.
81. van den Bogaard EH, Bergboer JG, Vonk-Bergers M, et al. Coal tar induces AHR-dependent skin barrier repair in atopic dermatitis. J Clin Invest. 2013;123(2):917-27.
82. Loeys BL, Gerber EE, Riegert-Johnson D, et al. Mutations in fibrillin-1 cause congenital scleroderma: stiff skin syndrome. Sci Transl Med. 2010;2(23):23ra20.
83. Arnett FC, Tan FK, Uziel Y, et al. Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin 1, in patients with localized scleroderma. Arthritis Rheum. 1999;42:2656-9.
84. Tan FK, Arnett FC, Antohi S, et al. Autoantibodies to the extracellular matrix microfibrillar protein, fibrillin-1, in patients with scleroderma and other connec-tive tissue diseases. J Immunol. 1999;163(2):1066-72.
85. Denton CP, Abraham DJ. Transforming growth factor-β and connective tissue growth factor: key cytokines in scleroderma pathogenesis. Curr Opin Rheumatol. 2001;13(6):505-11.
86. Freundlich B, Werth VP, Rook AH, et al. L-tryptophan ingestion associated with eosinophilic fasciitis but not progressive systemic sclerosis. Ann Intern Med. 1990;112:758-62.
87. Martin RW, Duffy J, Engel AG, et al. The clinical spectrum of the eosinophilia-myalgia syndrome associated with L-tryptophan ingestion. Ann Intern Med. 1990;113:124-34.
88. Smith SA, Pogson CI. Effects of benserazide and carbidopa on the metabolism of L-tryptophan by isolated rat liver cells. Biochem Pharmacol. 1981;30(6):623-8.
89. Perez MI, Kohn SR. Systemic sclerosis. J Am Acad Dermatol. 1993;28(4):525-47.
90. Noakes R, Mellick N. Immunohistochemical studies of the kynurenine pathway in morphea. Int J Tryptophan Res. 2013;6:97.
91. Yang X, Yang J, Xing X, Wan L, Li M. Increased frequency of Th17cells in sys-temic sclerosis is related to disease activity and collagen overproduction. Arthritis Res Ther. 2014;16(1):R4.
92. Skhirtladze C, Distler O, Dees C, et al. Src kinases in systemic sclerosis: central roles in fibroblast activation and in skin fibrosis. Arthritis Rheum. 2008;58(5):1475-84.
93. Elizondo G, Fernandez-Salguero P, Sheikh MS, et al. Altered cell cycle control at the G(2)/M phases in aryl hydrocarbon receptor-null embryo fibroblast. Mol Pharmacol. 2000;57(5):1056-63.
94. Fernandez-Salguero PM, Ward JM, Sundberg JP, Gonzalez FJ. Lesions of Aryl-hydrocarbon receptor-deficient mice. Vet Pathol. 1997;34(6):605-14.
95. Poskitt LB, Duffill MB, Rademaker M. Chloracne, palmoplantar kera-toderma and localized scleroderma in a weed sprayer. Clin Exp Dermatol. 1994;19(3):264-7.
96. Kreuter A, Hyun J, Stücker M, Sommer A, Altmeyer P, Gambichler T. A ran-domized controlled study of low-dose UVA1, medium-dose UVA1, and nar-rowband UVB phototherapy in the treatment of localized scleroderma. J Am Acad Dermatol. 2006;54(3):440-7.
97. Kerkvliet NI. AHR-mediated immunomodulation: the role of altered gene tran-scription. Biochem Pharmacol. 2009;77(4):746-60.
98. Ho PP, Steinman L. The aryl hydrocarbon receptor: a regulator of Th17 and Treg cell development in disease. Cell Res. 2008;18(6):605-8.
99. Lehmann GM, Xi X, Kulkarni AA, et al. The aryl hydrocarbon receptor ligand ITE inhibits TGFβ1-induced human myofibroblast differentiation. Am J Pathol. 2011;178(4):1556-67.
100. Sartori-Valinotti JC, Tollefson MM, Reed AM. Reed review article updates on morphea: role of vascular injury and advances in treatment. Autoimmune Dis. 2013;2013:8.
101. Yves R, Revelen R, Levy Y, et al. Anti-endothelial cell antibodies in systemic sclerosis. Clin Diagn Lab Immunol. 1999;6(2):156-60.
102. Dziankowski-Bartkowiak B, Zebrowska A, Wagrowski-Danielewicz M, Kobos J, Waszczykowska E. Systemic sclerosis and scleroderma circumscripta - distur-bances of selected serum parameters which are responsible for vascular changes and CD34 expression in involved skin. Przegl Lek. 2009;66(12):1040-5.
103. Marti LC, Pavon L, Severino P, Sibov T, Guilhen D, Moreira-Filho CA. Vascu-lar endothelial growth factor-A enhances indoleamine 2, 3-dioxygenase expres-sion by dendritic cells and subsequently impacts lymphocyte proliferation. Mem Inst Oswaldo Cruz. 2014;109(1):70-9.
104. Belladonna ML, Volpi C, Bianchi R, et al. Cutting edge: autocrine TGF-beta sustains default tolerogenesis by IDO-competent dendritic cells. J Immunol. 2008;181(8):5194-8.
105. Lacouture ME, Maitland ML, Segaert S, et al. A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxic-ity study group. Supportive Care Cancer. 2010;18(4):509-22.
106. Ito T, Inouye K, Nohara K, Tohyama C, Fujimaki H. TCDD exposure exac-erbates atopic dermatitis-related inflammation in NC/Nga mice. Toxicol Lett. 2008;177(1):31-7.
107. Krutmann J. Phototherapy for atopic dermatitis. Clin Exp Dermatol. 2000;25(7):552-8.
108. Kitamura R, Tsukamoto K, Harada K, et al. Mechanisms underlying the dys-function of melanocytes in vitiligo epidermis: role of SCF/KIT protein interac-tions and the downstream effector, MITF-M. J Pathol. 2004;202(4):463-75.
109. Passi S, Grandinetti M, Maggio F, Stancato A, De Luca C. Epidermal oxidative stress in vitiligo. Pigment Cell Res. 1998;11(2):81-5.
110. Bassiouny DA, Shaker O. Role of interleukin-17in the pathogenesis of vitiligo. Clin Exp Dermatol. 2011;36(3):292-7.
111. Wang XW, Li K, Guo S, et al. The association of functional polymorphisms in the aryl hydrocarbon receptor (AHR) gene with the risk of vitiligo in Han Chinese populations. Br J Dermatol. 2012;166(5):1081-7.
112. Nakamura M, Ueda Y, Hayashi M, Kato H, Furuhashi T, Morita A. Tobacco smoke-induced skin pigmentation is mediated by the aryl hydrocarbon receptor. Exp Dermatol. 2013;22(8):556-8.
113. Grichnik JM, Burch JA, Burchette J, Shea CR. The SCF/KIT pathway plays a critical role in the control of normal human melanocyte homeostasis. J Invest Dermatol. 1998;111(2):233-8.
114. Magiatis P, Pappas P, Gaitanis G, et al. Malassezia yeasts produce a collection of exceptionally potent activators of the Ah (dioxin) receptor detected in diseased human skin. J Invest Dermatol. 2013;133(8):2023-30.
115. Coltman CA, Rowe NJ, Atwell RJ. The amino acid content of sweat in normal adults. Am J Clin Nutr. 1966;18(5):373-8.
116. Magiatis P, Mexia N, Galanou M, et al. Malassezia spp. extracts and metabolites induce the AhR dependent genes in HaCaT cells. Planta Med. 2009;75(9):A33.
117. Krämer HJ, Podobinska M, Bartsch A, et al. Malassezin, a novel agonist of the aryl hydrocarbon receptor from the yeast Malassezia furfur, induces apoptosis in primary human melanocytes. Chembiochem. 2005;6(5):860-5.
118. Gaitanis G, Magiatis P, Stathopoulou K, et al. AhR ligands, malassezin, and indolo[3,2-b]carbazole are selectively produced by Malassezia furfur strains iso-lated from seborrheic dermatitis. J Invest Dermatol. 2008;128(7):1620-5.
119. Hankinson O. The aryl hydrocarbon receptor complex. Annu Rev Pharmacol Toxicol. 1995;35(1):307-40.
120. Giménez-García R, Ánchez-Ramón SS, Cuellar-Olmedo LA. Palmoplantar pustulosis: a clinicoepidemiological study. The relationship between tobacco use and thyroid function. J Eur Acad Dermatol Venereol. 2003;17(3):276-9.
121. Murakami M, Hagforsen E, Morhenn V, Ishida-Yamamoto A, Iizuka H. Patients with palmoplantar pustulosis have increased IL-17 and IL-22 levels both in the lesion and serum. Exp Dermatol. 2011;20(10):845-7.
122. Simonart T. Hidradenitis suppurativa and smoking. J Am Acad Dermatol. 2010;62(1):149-50.
123. Kamp S, Fiehn AM, Stenderup K, et al. Hidradenitis suppurativa: a disease of the absent sebaceous gland? Sebaceous gland number and volume are signifi-cantly reduced in uninvolved hair follicles from patients with hidradenitis sup-purativa. Br J Dermatol. 2011;164(5):1017-22.